Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leukemia: early-phase trial registry
51 of 274 indexed Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #35 of 28,707 conditions by registered trial count.
274 US clinical trials · 51 currently recruiting · #35 of 28,707 conditions by registered trial count
Leukemia: 274 US clinical trials tracked, 51 recruiting.
Leukemia is the subject of 274 registered US clinical trials on ClinicalTrials.gov, 51 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 193 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 37 of these trials.
Enrollment posture brief
Registry condition leukemia
OPEN 51 | RECR 19% | LATE 19 | EARLY 193 | RANK #35 | SPON 37
Volume-matched condition peers
Nearest open-share peer: Rheumatoid Arthritis (19% recruiting · 199 trials)
Leukemia lists 51 open slots (19% of 274 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leukemia is recruiting below its size-band peers.
51 of 274 indexed trials (18.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 37 of 274 trials (13.5%). 84 distinct sponsors appear on at least one study for this condition label.
-
Most Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 234 trials that report a genuine target (sentinel values excluded). 170 of those (72.6%) plan for fewer than 100 participants.
-
Leukemia research is mostly interventional.
243 interventional and 31 observational studies make up this index (88.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
274 total, page 2 of 6
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
NCT00935090
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group
Children's Oncology Group
NCT01117168
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
NCT00579163
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
Alliance for Clinical Trials in Oncology
NCT00003861
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
NCT00898456
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Memorial Sloan Kettering Cancer Center
NCT02450708
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Children's Oncology Group
NCT03057054
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
Children's Hospital of Philadelphia
NCT02323867
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
NCT01446133
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02530463
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
NCT01044069
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
NCT01500733
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
NCT02251548
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT01746849
A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Seattle Children's Hospital
NCT03330691
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
City of Hope Medical Center
NCT00544466
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax
NCT04977024
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Baylor College of Medicine
NCT00881920
AZD6738 for Patients With Progressive MDS or CMML
Massachusetts General Hospital
NCT03770429
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
City of Hope Medical Center
NCT00576979
Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors
St. Jude Children's Research Hospital
NCT06053268
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
NCT00466531
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
Seattle Children's Hospital
NCT04571138
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
NCT06021600
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT01920737
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
NCT05871008
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
NCT03410875
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
H. Lee Moffitt Cancer Center and Research Institute
NCT03722407
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT05268003
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
Memorial Sloan Kettering Cancer Center
NCT03793140
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
NCT05763563
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Seattle Children's Hospital
NCT03684889
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Takeda
NCT05886491
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
NCT02932280
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Dana-Farber Cancer Institute
NCT03974217
Pilot of a Trial Enrollment Diversity Dashboard
Dana-Farber Cancer Institute
NCT06795139
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT02477878
A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
Seattle Children's Hospital
NCT03244306
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
Children's Oncology Group
NCT00005945
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
Children's Oncology Group
NCT00002812
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
Takeda
NCT05743465
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
National Cancer Institute (NCI)
NCT00339963
S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
SWOG Cancer Research Network
NCT00919425
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Eastern Cooperative Oncology Group
NCT00002868
Case-Control Study of Pesticides and Childhood Leukemia
National Cancer Institute (NCI)
NCT00342888
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
Mayo Clinic
NCT00661999
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant
City of Hope Medical Center
NCT00964821
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
Alliance for Clinical Trials in Oncology
NCT00896701
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
National Cancer Institute (NCI)
NCT00002925
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
NCT00003816
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 98 |
| Phase 2 | 95 |
| Phase 3 | 18 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leukemia page
274 registered trials, 51 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 51 Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukemia condition card totals 274 registered trials; most-linked intervention cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.